DK3345904T3 - Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet - Google Patents

Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet Download PDF

Info

Publication number: DK3345904T3
Authority: DK; Denmark
Prior art keywords: beta2; compounds; agonist activity; receptor antagonist; receptor agonist
Prior art date: 2012-12-06

Application number

DK18156043.4T

Other languages

English (en)

Inventor

Fabio Rancati

Ian Linney

Original Assignee

Chiesi Farm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-06

Filing date

2013-12-05

Publication date

2020-08-31

2013-12-05 Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa

2020-08-31 Application granted granted Critical

2020-08-31 Publication of DK3345904T3 publication Critical patent/DK3345904T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms

DK18156043.4T 2012-12-06 2013-12-05 Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet DK3345904T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12195891		2012-12-06
EP13811827.8A EP2928889B1 (en)	2012-12-06	2013-12-05	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Publications (1)

Publication Number	Publication Date
DK3345904T3 true DK3345904T3 (da)	2020-08-31

Family

ID=47323975

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13811827.8T DK2928889T3 (da)	2012-12-06	2013-12-05	Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptorantagonistaktivitet
DK18156043.4T DK3345904T3 (da)	2012-12-06	2013-12-05	Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK13811827.8T DK2928889T3 (da)	2012-12-06	2013-12-05	Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptorantagonistaktivitet

Country Status (38)

Country	Link
US (2)	US8987299B2 (da)
EP (2)	EP2928889B1 (da)
JP (1)	JP6421989B2 (da)
KR (2)	KR102156443B1 (da)
CN (1)	CN104822678B (da)
AR (1)	AR093825A1 (da)
AU (1)	AU2013354043C1 (da)
BR (1)	BR112015012730B1 (da)
CA (1)	CA2893626C (da)
CL (1)	CL2015001483A1 (da)
CO (1)	CO7400870A2 (da)
CY (2)	CY1120159T1 (da)
DK (2)	DK2928889T3 (da)
EA (1)	EA030552B1 (da)
ES (2)	ES2816210T3 (da)
GE (1)	GEP20186839B (da)
HK (1)	HK1212989A1 (da)
HR (2)	HRP20180915T1 (da)
HU (2)	HUE037944T2 (da)
IL (1)	IL239182B (da)
LT (2)	LT3345904T (da)
MA (1)	MA38147B1 (da)
MX (1)	MX369311B (da)
NZ (1)	NZ708738A (da)
PE (1)	PE20151216A1 (da)
PH (1)	PH12015501247B1 (da)
PL (2)	PL3345904T3 (da)
PT (2)	PT2928889T (da)
RS (2)	RS57232B1 (da)
SA (1)	SA515360514B1 (da)
SG (2)	SG11201504318UA (da)
SI (2)	SI3345904T1 (da)
TN (1)	TN2015000244A1 (da)
TR (1)	TR201808698T4 (da)
TW (1)	TWI637954B (da)
UA (1)	UA118181C2 (da)
WO (1)	WO2014086924A1 (da)
ZA (1)	ZA201503965B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	Piastra per la costruzione di carrelli per aeroplani
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
CN104854105B (zh) *	2012-12-06	2017-05-17	奇斯药制品公司	具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
MA38147B1 (fr) *	2012-12-06	2018-09-28	Chiesi Farm Spa	Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
SG11201504452WA (en)	2012-12-18	2015-07-30	Almirall Sa	New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
TWI643853B (zh)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh)	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) *	2015-02-12	2020-09-01	義大利商吉斯藥品公司	具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es)	2015-06-01	2017-08-16	Chiesi Farm Spa	COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
DK3628331T3 (da) *	2015-11-16	2021-09-27	Chiesi Farm Spa	Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum
EP3383867B1 (en)	2015-12-03	2021-04-14	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3484879B1 (en)	2016-07-13	2020-12-30	Chiesi Farmaceutici S.p.A.	Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CA2994290C (en)	2017-11-06	2024-01-23	Entech Solution As	Method and stimulation sleeve for well completion in a subterranean wellbore

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2222128A (en)	1937-01-29	1940-11-19	Pure Oil Co	Preparation and separation of aromatic hydrocarbons
DE19921693A1 (de)	1999-05-12	2000-11-16	Boehringer Ingelheim Pharma	Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
JP4490911B2 (ja)	2002-10-11	2010-06-30	ファイザー・インク	β−２アゴニストとしてのインドール誘導体
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN100569760C (zh)	2003-11-21	2009-12-16	施万制药	具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
PL1708992T3 (pl)	2004-01-22	2007-12-31	Pfizer	Pochodne sulfonamidów do leczenia chorób
WO2005092861A1 (en)	2004-03-11	2005-10-06	Pfizer Limited	Quinolinone derivatives pharmaceutical compositions containing them and their use
US7538141B2 (en)	2004-03-23	2009-05-26	Alan Daniel Brown	Compounds for the treatment of diseases
EP1730103B1 (en)	2004-03-23	2010-05-26	Pfizer Limited	Formamide derivatives useful as adrenoceptor
ES2257152B1 (es) *	2004-05-31	2007-07-01	Laboratorios Almirall S.A.	Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1778626A1 (en)	2004-08-16	2007-05-02	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1833822A2 (en)	2004-08-16	2007-09-19	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
FR2898640B1 (fr)	2006-03-20	2008-04-25	Siemens Vdo Automotive Sas	Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
EP2080523A1 (en) *	2008-01-15	2009-07-22	CHIESI FARMACEUTICI S.p.A.	Compositions comprising an antimuscarinic and a long-acting beta-agonist
SI2599778T1 (sl)	2009-04-23	2017-08-31	Theravance Respiratory Company, Llc	Diamidne spojine, ki imajo muskarinski receptor-antagonistično in beta 2 adrenergični receptor-agonistično aktivnost
WO2010126025A1 (ja) *	2009-04-30	2010-11-04	帝人ファーマ株式会社	四級アンモニウム塩化合物
WO2011048409A1 (en)	2009-10-20	2011-04-28	Astrazeneca Ab	Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP2718281B1 (en)	2011-06-10	2015-09-09	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ME02297B (me) *	2011-06-10	2016-02-20	Chiesi Farm Spa	Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
MA38147B1 (fr) *	2012-12-06	2018-09-28	Chiesi Farm Spa	Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
CN104854105B (zh) *	2012-12-06	2017-05-17	奇斯药制品公司	具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物

2013
- 2013-12-05 MA MA38147A patent/MA38147B1/fr unknown
- 2013-12-05 DK DK13811827.8T patent/DK2928889T3/da active
- 2013-12-05 PT PT138118278T patent/PT2928889T/pt unknown
- 2013-12-05 NZ NZ708738A patent/NZ708738A/en not_active IP Right Cessation
- 2013-12-05 BR BR112015012730-4A patent/BR112015012730B1/pt active IP Right Grant
- 2013-12-05 SI SI201331764T patent/SI3345904T1/sl unknown
- 2013-12-05 HU HUE13811827A patent/HUE037944T2/hu unknown
- 2013-12-05 PE PE2015000738A patent/PE20151216A1/es active IP Right Grant
- 2013-12-05 PL PL18156043T patent/PL3345904T3/pl unknown
- 2013-12-05 LT LTEP18156043.4T patent/LT3345904T/lt unknown
- 2013-12-05 AU AU2013354043A patent/AU2013354043C1/en active Active
- 2013-12-05 EP EP13811827.8A patent/EP2928889B1/en active Active
- 2013-12-05 LT LTEP13811827.8T patent/LT2928889T/lt unknown
- 2013-12-05 CA CA2893626A patent/CA2893626C/en active Active
- 2013-12-05 HU HUE18156043A patent/HUE051394T2/hu unknown
- 2013-12-05 PL PL13811827T patent/PL2928889T3/pl unknown
- 2013-12-05 AR ARP130104529A patent/AR093825A1/es unknown
- 2013-12-05 ES ES18156043T patent/ES2816210T3/es active Active
- 2013-12-05 WO PCT/EP2013/075661 patent/WO2014086924A1/en active Application Filing
- 2013-12-05 TR TR2018/08698T patent/TR201808698T4/tr unknown
- 2013-12-05 SG SG11201504318UA patent/SG11201504318UA/en unknown
- 2013-12-05 GE GEAP201313845A patent/GEP20186839B/en unknown
- 2013-12-05 MX MX2015006788A patent/MX369311B/es active IP Right Grant
- 2013-12-05 RS RS20180529A patent/RS57232B1/sr unknown
- 2013-12-05 RS RS20201150A patent/RS60864B1/sr unknown
- 2013-12-05 KR KR1020157014956A patent/KR102156443B1/ko active IP Right Grant
- 2013-12-05 EA EA201590873A patent/EA030552B1/ru unknown
- 2013-12-05 PT PT181560434T patent/PT3345904T/pt unknown
- 2013-12-05 EP EP18156043.4A patent/EP3345904B1/en active Active
- 2013-12-05 JP JP2015546012A patent/JP6421989B2/ja active Active
- 2013-12-05 KR KR1020207006181A patent/KR102240459B1/ko active IP Right Grant
- 2013-12-05 ES ES13811827.8T patent/ES2670686T3/es active Active
- 2013-12-05 CN CN201380063365.2A patent/CN104822678B/zh active Active
- 2013-12-05 SG SG10201704032RA patent/SG10201704032RA/en unknown
- 2013-12-05 SI SI201330994T patent/SI2928889T1/en unknown
- 2013-12-05 UA UAA201505478A patent/UA118181C2/uk unknown
- 2013-12-05 TW TW102144561A patent/TWI637954B/zh not_active IP Right Cessation
- 2013-12-05 DK DK18156043.4T patent/DK3345904T3/da active
- 2013-12-06 US US14/098,735 patent/US8987299B2/en active Active
2015
- 2015-01-23 US US14/603,926 patent/US9371318B2/en active Active
- 2015-06-02 CL CL2015001483A patent/CL2015001483A1/es unknown
- 2015-06-03 SA SA515360514A patent/SA515360514B1/ar unknown
- 2015-06-03 TN TNP2015000244A patent/TN2015000244A1/fr unknown
- 2015-06-03 ZA ZA2015/03965A patent/ZA201503965B/en unknown
- 2015-06-03 IL IL239182A patent/IL239182B/en active IP Right Grant
- 2015-06-03 PH PH12015501247A patent/PH12015501247B1/en unknown
- 2015-06-03 CO CO15127118A patent/CO7400870A2/es unknown
2016
- 2016-01-29 HK HK16101057.0A patent/HK1212989A1/zh unknown
2018
- 2018-05-03 CY CY20181100469T patent/CY1120159T1/el unknown
- 2018-06-13 HR HRP20180915TT patent/HRP20180915T1/hr unknown
2020
- 2020-09-09 HR HRP20201435TT patent/HRP20201435T1/hr unknown
- 2020-09-28 CY CY20201100912T patent/CY1123365T1/el unknown

Also Published As

Publication number	Publication date
PL2928889T3 (pl)	2018-09-28
TWI637954B (zh)	2018-10-11
TW201427976A (zh)	2014-07-16
TR201808698T4 (tr)	2018-07-23
MX2015006788A (es)	2015-08-05
PT3345904T (pt)	2020-09-07
BR112015012730A2 (pt)	2017-07-11
UA118181C2 (uk)	2018-12-10
MA38147B1 (fr)	2018-09-28
SG10201704032RA (en)	2017-06-29
EP2928889B1 (en)	2018-03-21
US8987299B2 (en)	2015-03-24
IL239182A0 (en)	2015-07-30
CY1120159T1 (el)	2018-12-12
US9371318B2 (en)	2016-06-21
ZA201503965B (en)	2016-09-28
JP2016502557A (ja)	2016-01-28
RS57232B1 (sr)	2018-07-31
SI2928889T1 (en)	2018-05-31
HRP20180915T1 (hr)	2018-07-27
DK2928889T3 (da)	2018-05-22
AR093825A1 (es)	2015-06-24
EA201590873A1 (ru)	2015-09-30
EA030552B1 (ru)	2018-08-31
EP3345904A1 (en)	2018-07-11
CN104822678A (zh)	2015-08-05
KR20150090108A (ko)	2015-08-05
KR20200027049A (ko)	2020-03-11
PE20151216A1 (es)	2015-09-08
GEP20186839B (en)	2018-04-10
ES2670686T3 (es)	2018-05-31
PH12015501247A1 (en)	2015-08-17
NZ708738A (en)	2019-02-22
EP2928889A1 (en)	2015-10-14
PH12015501247B1 (en)	2015-08-17
HUE051394T2 (hu)	2021-03-01
SA515360514B1 (ar)	2016-08-30
SI3345904T1 (sl)	2020-09-30
PT2928889T (pt)	2018-05-29
MA38147A1 (fr)	2018-03-30
AU2013354043B2 (en)	2017-06-15
HRP20201435T1 (hr)	2020-11-27
PL3345904T3 (pl)	2020-12-14
CA2893626C (en)	2021-08-24
CN104822678B (zh)	2017-03-08
EP3345904B1 (en)	2020-07-29
HK1212989A1 (zh)	2016-06-24
JP6421989B2 (ja)	2018-11-14
TN2015000244A1 (en)	2016-10-03
IL239182B (en)	2018-12-31
RS60864B1 (sr)	2020-11-30
US20150133491A1 (en)	2015-05-14
SG11201504318UA (en)	2015-07-30
WO2014086924A1 (en)	2014-06-12
KR102156443B1 (ko)	2020-09-17
LT2928889T (lt)	2018-06-11
KR102240459B1 (ko)	2021-04-16
HUE037944T2 (hu)	2018-09-28
CO7400870A2 (es)	2015-09-30
CY1123365T1 (el)	2021-12-31
MX369311B (es)	2019-11-05
ES2816210T3 (es)	2021-03-31
AU2013354043C1 (en)	2017-08-31
US20140161736A1 (en)	2014-06-12
CA2893626A1 (en)	2014-06-12
BR112015012730B1 (pt)	2022-07-05
LT3345904T (lt)	2020-09-25
CL2015001483A1 (es)	2015-10-23

Publication	Publication Date	Title
DK3345904T3 (da)	2020-08-31	Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet
CO6821950A2 (es)	2013-12-31	Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
PL2928890T3 (pl)	2018-07-31	Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
DK2421849T3 (da)	2013-07-01	Diamidforbindelser med muscarinreceptorantagonist- og beta2-adrenoreceptoragonist-virkning
BR112014027348A2 (pt)	2017-06-27	compostos agonistas duplos gip-glp-1 e métodos
HK1252279A1 (zh)	2019-05-24	5- ht3受體拮抗劑
ZA201509203B (en)	2017-04-26	Salts of2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1h)-one derivatives having both muscarinic receptor antagonist and b2 adrenergic receptor agonist activities
KR20180085068A (ko)	2018-07-25	무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
DK2821407T3 (da)	2017-01-02	Piperidinoncarboxamidazaindan-cgrp receptorantagonister
CO6821953A2 (es)	2013-12-31	Antagonistas de trpv4
DK3024474T3 (da)	2022-03-28	Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist